Abbott Laboratories (ABT) $108.00
Abbott is currently riding a massive 19.8% three-month wave, but with the RSI screaming overbought at 74.6, the stock is now a high-stakes game of musical chairs.
52-wk High $137.49
📌 Investment Snapshot
- Current price of $108.00 trades at a 35.0x P/E, reflecting a significant growth premium.
- Q1 2026 revenue hit $11.16B with EPS of $0.62, showing steady top-line stability.
- Technical Confluence Score of 100/100 confirms a perfect alignment of momentum indicators.
- Wall Street maintains a $118.42 mean target, implying a 9.6% remaining runway.
⏳ WAIT
Abbott has reclaimed its 200-day moving average following a violent 17% monthly rally. However, the extreme RSI levels and proximity to the upper Bollinger Band suggest the easy money has been made for this leg.
| 📍 Entry Zone | $104.18 or below | 🛑 Stop-Loss | $98.50 |
| 📋 Adjust If | RSI cools below 60 while price holds the $105.86 Bullish FVG. | ||
The Investment Case — Why Now?
Over the last 90 days, Abbott shifted from a laggard to a momentum darling as institutional accumulation accelerated. The stock successfully filled its bearish gap from mid-July and converted previous resistance at the $107 SMA200 into new support.
The primary risk centers on the 35.0x P/E ratio, which sits nearly 40% above historical medians for the medical device sector. If the 10Y Treasury yield remains sticky at 4.64%, this valuation premium faces a potential compression event during the October earnings cycle.
Can Abbott’s pipeline growth justify a 35x multiple in a 4.6% interest rate environment?
🤔 Can Abbott’s pipeline growth justify a 35x multiple in a 4.6% interest rate environment?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Dividend Yield | 2.35% |
| Short Interest | 1.6% |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $89.97 on 2026-07-15
The price recently reclaimed the SMA200 ($107.20), a critical psychological pivot that often separates bull and bear markets. This move confirms a structural trend shift, though the distance from the SMA50 ($92.11) suggests the stock is overextended.
Momentum is undeniably bullish with the RSI at 74.6, yet this level historically precedes a period of consolidation or a ‘cooling off’ phase. The ADX at 32.0 confirms a strong trend is in place, while the +DI dominance shows buyers are firmly in control.
The Anchored VWAP at $91.38 remains far below current levels, indicating that the average buyer from the May lows is sitting on significant gains. We expect these participants to begin trimming positions as the stock approaches the $110 psychological resistance.
Three unfilled Bullish Fair Value Gaps (FVG) exist between $101.90 and $106.97, serving as magnetic zones for a potential mean reversion. A dip into the $104.18~$105.97 FVG would offer a much healthier entry point than chasing at current prices.
Volatility is expanding as price tags the upper Bollinger Band ($109.06), while the volume ratio of 0.93x suggests this latest push lacks the ‘blow-off top’ volume typically seen at exhaustion. This implies a slow grind higher or a sideways flag is more likely than a sharp crash.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ABT | Abbott Laboratories | 35.0x |
| TMO | Thermo Fisher | 31.2x |
| MDT | Medtronic | 28.5x |
| SPY | S&P 500 Avg | 22.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $11.16B | $0.62 | +0.2% |
| Q4 2025 | $11.46B | $1.02 | +2.1% |
| Q3 2025 | $11.37B | $0.95 | +1.8% |
| Q2 2025 | $11.14B | $1.02 | +1.5% |
Abbott generated $0.9B in free cash flow last quarter, maintaining its status as a cash cow. The company returned $0.2B to shareholders via buybacks, though this pace has slowed compared to 2024 levels.
Revenue has remained remarkably consistent, oscillating between $11.1B and $11.4B over the last four quarters. While the stability is commendable, the lack of explosive top-line growth makes the current 35x P/E multiple difficult to defend long-term.
🚀 Growth Drivers — What Moves the Stock
- FreeStyle Libre Expansion 🟡 Priced In — Continued dominance in the continuous glucose monitoring market remains the primary engine for organic growth.
- Medical Device Pipeline 🟢 Upside Surprise — New FDA approvals in the structural heart segment could provide a surprise revenue lift in late 2026.
🤔 Would you prioritize Abbott’s 2.35% dividend yield over the potential for higher growth in smaller med-tech peers?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 145,687 |
| Vanguard Capital Management LLC | 112,949 |
| State Street Corporation | 79,575 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| STARKS DANIEL J | Director | 2026-04-27 | Purchase | 10000 |
| STRATTON JOHN G. | Director | 2026-05-07 | Purchase | 2000 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 1.6% | 1.8 |
⚠ Key Risk Factors
~$15B impact
~$8B impact
🎯 Guidance & Wall Street View
Management has signaled a focus on margin expansion through 2026, targeting a return to double-digit EPS growth by optimizing the manufacturing footprint.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $135.00 | $118.42 | $103.00 | 24 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| UBS | Buy | $125.00 | 2026-07-28 | Maintained |
| JP Morgan | Overweight | $120.00 | 2026-07-17 | Maintained |
Analysts remain overwhelmingly bullish, with 24 firms maintaining a ‘Buy’ consensus despite the recent price surge. The mean target suggests another 9.6% of upside remains.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Successful breakout above SMA200 signals institutional re-entry.
- FreeStyle Libre 3 adoption exceeds expectations in European markets.
📊 Base Case
Abbott consolidates between $104 and $110 as the market digests recent gains.
🐻 Bear Case
- RSI divergence leads to a sharp mean reversion toward the $92 SMA50.
- Q3 earnings miss on revenue due to softening diagnostic demand.
🎯 Investor Action Plan — By Profile
The risk/reward is poor at $108 with an RSI over 74. Staying on the sidelines until the stock tests the $104 Bullish FVG or the $107 SMA200 support level.
Current holders should stay the course but tighten stop-losses to $103. The trend is strong, but the valuation premium warrants caution on new capital.
Wait for a broader market pullback to secure a better entry. Buying a 35x P/E stock at its local peak rarely yields market-beating long-term returns.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why is ABT stock rising despite high interest rates?
Investors are rotating into high-quality healthcare names with stable cash flows and reliable dividends as a defensive play against broader market volatility.
Q: What is the key technical level to watch for Abbott?
The $107.20 level (SMA200) is the line in the sand; as long as ABT stays above this, the technical outlook remains structurally bullish.
Q: Is the 2.35% dividend safe?
Yes, with $0.9B in quarterly free cash flow and a conservative payout ratio, Abbott’s dividend remains one of the safest in the healthcare sector.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 For real-time updates and advanced charting tools,
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#ABT #AbbottLabs #HealthcareStocks #Investing #StockMarket #TechnicalAnalysis #WallStreet